Summary
Johnson & Johnson reported solid financial results for the fiscal second quarter and first six months ended July 2, 2006. Sales increased by 4.7% to $13.4 billion for the quarter and 3.0% to $26.4 billion for the six-month period, driven by strong performance across its Pharmaceutical and Medical Devices & Diagnostics segments, particularly in the U.S. and Western Hemisphere markets. Net earnings for the quarter rose to $2.8 billion ($0.96 per share) from $2.6 billion ($0.87 per share) in the prior year, reflecting overall operational strength. The company also announced a significant agreement to acquire Pfizer's Consumer Healthcare business for $16.6 billion, signaling a strategic move to expand its consumer offerings. The company continues to return value to shareholders through increasing dividends and an active share repurchase program.
Key Highlights
- 1Worldwide sales increased by 4.7% to $13.4 billion in Q2 2006 and 3.0% to $26.4 billion in the first six months of 2006 compared to the prior year periods.
- 2Net earnings for Q2 2006 were $2.8 billion ($0.96 per share), up from $2.6 billion ($0.87 per share) in Q2 2005.
- 3The company announced a definitive agreement to acquire Pfizer's Consumer Healthcare business for $16.6 billion.
- 4The Pharmaceutical segment showed robust growth, driven by strong sales of RISPERDAL/RISPERDAL CONSTA, REMICADE, and TOPAMAX.
- 5The Medical Devices & Diagnostics segment also performed well, with the CYPHER Sirolimus-eluting Stent being a key growth driver.
- 6Johnson & Johnson declared a regular quarterly cash dividend of $0.375 per share, a 13.6% increase, marking the 44th consecutive year of dividend increases.
- 7The company repurchased approximately 43 million shares of common stock during the second quarter of 2006.